If you have been reading about cyclic heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-03. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
=== Radiogenic === Some 209Bi was created radiogenically from the neptunium decay chain. Neptunium-237 is an extinct radionuclide, but it can be found in traces in uranium ores because of neutron capture reactions. This is also ultimately due to the r-process, as every (4n+1) nucleus formed (and not fissioned) ultimately decayed to bismuth.
== PCSK subtypes == To date there are 9 PCSKs with varying functions and tissue distributions. Often, due to similar times of discovery from different groups the same PCSKs have acquired multiple names. In an attempt to alleviate confusion, there is a trend towards using the PCSK prefix with the appropriate number suffix.
Adrien-Marie Legendre at PlanetMath. The True Face of Adrien-Marie Legendre (Portrait of Legendre) Biography at Fermat's Last Theorem Blog References for Adrien-Marie Legendre (in French) Eléments de géométrie (Paris : F. Didot, 1817) Elements of geometry and trigonometry, from the works of A. M. Legendre. Revised and adapted to the course of mathematical instruction in the United States, by Charles Davies. (New York: A. S. Barnes & co., 1858) : English translation of the above text Mémoires sur la méthode des moindres quarrés, et sur l'attraction des ellipsoïdes homogènes (1830) Théorie des nombres (Paris : Firmin-Didot, 1830) Traité des fonctions elliptiques et des intégrales eulériennes (Paris : Huzard-Courcier, 1825–1828) Nouvelles Méthodes pour la Détermination des Orbites des Comètes (Paris : Courcier, 1806) Essai sur la Théorie des Nombres (Paris : Duprat, 1798) Exercices de Calcul Intégral V.3 (Paris : Courcier, 1816) Correspondance mathématique avec Legendre in C. G. J. Jacobis gesammelte Werke (Berlin: 1852)
The RCMP Security Service (French: Service de sécurité de la GRC) was a branch of the Royal Canadian Mounted Police (RCMP) that had responsibility for domestic intelligence and security in Canada. It was replaced by the Canadian Security Intelligence Service (CSIS) in 1984 on the recommendation of the McDonald Commission, which was called in the wake of major scandals during the 1970s.
Some people, however, can continue to lose potassium while on an ACE inhibitor. Hyperkalemia may decrease the velocity of impulse conduction in the nerves and muscles, including cardiac tissues. This leads to cardiac dysfunction and neuromuscular consequences, such as muscle weakness, paresthesia, nausea, diarrhea, and others. Close monitoring of potassium levels is required in patients receiving treatment with ACE inhibitors who are at risk of hyperkalemia. Another possible adverse effect specific for ACE inhibitors, but not for other RAAS blockers, is an increase in bradykinin level. Additional research on this topic is required. A persistent dry cough is a common adverse effect produced by ACE inhibitors in 10% to 20% of patients. People who experience coughing are often switched to angiotensin II receptor antagonists. Between 0.1% and 0.7% of patients develop angioedema or swelling. A genetic predisposition may exist.
Sources: en.wikipedia.org
In the 2021 Census of Population conducted by Statistics Canada, the census districts within the former city had a population of 629,941 living in 218,928 of its 228,939 total private dwellings, a change of −0.3% from its 2016 population of 632,098. With a land area of 187.70 square kilometres (72.47 sq mi), it had a population density of 3,356.1 people/km2 (8,692 people/sq mi) in 2021. The majority of the district's population is between 25 and 64 years old. 52% fell into that "working age" during the last major survey, which also found 21% of Scarborough's population was 14 years old or younger, 15% were between 15 and 24, while senior citizens aged 65+ made up the remaining 12%. Like the rest of Canada, the population is aging. It is projected that close to 30% of Scarborough residents will be senior citizens by 2041. Scarborough has a large number of retirement communities, which attracts more seniors to the area creating a situation where the two largest age demographics in Scarborough will be over 55 and under 25.
Arguing it was the French or Westphalian state and not Hanover, which had emancipated the Jews, the government took the decisions of the German Confederation on the rights of the Jews, in Johann Smidt's manipulated formulation, as the legal grounds. In 1842, Hanover finally granted equal rights to Jews and promoted building up Jewish congregations, where this did not already happen earlier, and a superstructure of four regional land-rabbinates. These were the Emden Land-Rabbinate (Aurich and Osnabrück regions), the Hanover Land-Rabbinate (Hanover and Lüneburg regions), the Hildesheim Land-Rabbinate (Hildesheim region and Clausthal Mountain Captaincy), and the Stade Land-Rabbinate (Stade region). In many diaspora areas, Jews regarded this as progress and a burden alike, because of the implied financial burden for rabbis and religion teacher, synagogues or schools. The local authorities now requested that the Jewish congregations establish synagogues and Jewish education for the pupils. The land-rabbins, chairing the land-rabbinates, simultaneously fulfilled religious and state functions, like supervising Jewish elementary schools and the teaching of Jewish religion in all schools. The Kingdom of Hanover was thus one of the few states within the German Confederation, where rabbins held a similar semi-state authoritative position as to Jews as did, e.g., Lutheran clergy towards Lutherans.
=== Stability === Thionyl chloride has a long shelf life, however "aged" samples develop a yellow hue, possibly due to the formation of disulfur dichloride. It slowly decomposes to S2Cl2, SO2 and Cl2 at just above the boiling point. Thionyl chloride is susceptible to photolysis, which primarily proceeds via a radical mechanism. Samples showing signs of ageing can be purified by distillation under reduced pressure, to give a colourless liquid.
Alcohol interacts with cocaine in vivo to produce cocaethylene, another psychoactive substance which may be substantially more cardiotoxic than either cocaine or alcohol by themselves. In 2024, a systematic review of human studies concluded that, despite some inconsistencies in the findings, the co-use of cocaine and alcohol poses a significantly greater risk of cardiovascular fatalities compared to cocaine use alone. This elevated risk is largely attributed to the formation of cocaethylene, a unique and toxic metabolite produced only when both substances are consumed together. Cocaethylene is associated with an 18- to 25-fold increased risk of sudden death, as well as a higher incidence of myocardial injury and cardiac arrest, underscoring the serious health risks of simultaneous cocaine and alcohol use.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.